Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2015;65:87-108
   PubMed Web of Science ®Google Scholar
• Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 2010;7:e1000279
   PubMed Web of Science ®Google Scholar
• Guiu S, Coudert B, Favier L, et al. Management of metastatic HER2-positive breast cancer: present and future. Bull Cancer 2010;97:365-83
   PubMed Web of Science ®Google Scholar
• Santa-Maria CA, Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncology 2015;1:528-34
   PubMedGoogle Scholar
• Rogers G, Hoyle MC, Moxham JT, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess 2012;16:1-410
   Google Scholar
• Thompson Coon J, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010;14(2):i–iv
   Google Scholar
• Mangan. D. (2013, June 25). Medical bills are the biggest cause of us bankruptcies: Study. CNBC Health Care. Retrieved from http://www.cnbc.com/id/100840148. Last accessed 20 November 2015
   Google Scholar
• Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. Pharmacoeconomics 2014;32:101-8
   PubMed Web of Science ®Google Scholar
• Swain SM, Kim S, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology 2013;14:461-71
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-91
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol 2012;12:9
   Google Scholar
• Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974;19:716-23
   Web of Science ®Google Scholar
• Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4
   Web of Science ®Google Scholar
• Moeschberger ML, Klein J. Survival Analysis: Techniques for Censored and Truncated Data: Statistics for Biology and Health. Springer, 2003
   Google Scholar
• Walzer S, Chouaid C, Lister J, et al. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Rev Anticanc Ther 2014;15:121-8
   PubMed Web of Science ®Google Scholar
• Hannink G, Gooszen HG, van Laarhoven CJ, Rovers MM. A systematic review of individual patient data meta-analyses on surgical interventions. Syst Rev 2013;2:52
   Google Scholar
• Stewart LA, Tierney JF. To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof 2002;25:76-97
   PubMed Web of Science ®Google Scholar
• Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials 2009;6:16-27
   PubMed Web of Science ®Google Scholar
• Montori VM, Swiontkowski MF, Cook DJ. Methodologic issues in systematic reviews and meta-analyses. Clin Orthop Relat Res 2003;413:43-54
   PubMed Web of Science ®Google Scholar
• Clarke MJ, Stewart L, Tierney J, Williamson PR. Individual Patient Data Meta-analyses Compared with Meta-analyses Based on Aggregate Data. The Cochrane Library, 2007
   Google Scholar
• Sutton AJ, Kendrick D, Coupland CA. Meta-analysis of individual- and aggregate-level data. Stat Med 2008;27:651-69
   PubMed Web of Science ®Google Scholar
• Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One 2010;5:e11054
   Google Scholar
• Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health 2014;17:157-73
   PubMed Web of Science ®Google Scholar
• Donegan S, Williamson P, D’Alessandro U, et al. Combining individual patient data and aggregate data in mixed treatment comparison meta-analysis: individual patient data may be beneficial if only for a subset of trials. Stat Med 2013;32:914-30
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Andrew PY, et al. Comparative effectiveness without head-to-head trials. Pharmacoeconomics 2010;28:935-45
   PubMed Web of Science ®Google Scholar